45 results about "Receptor-mediated endocytosis" patented technology

The fiber protein of adenovirus has been genetically altered via attachment at the carboxyl end of a peptide linker, preferably up to 26 amino acids in length which forms a random coil, which can be used to attach a non-adenovirus ligand altering the binding specificity of the fiber protein. Examples of ligands include peptides which are selectively bound by a targeted cell so that the modified fiber protein is internalized by receptor-mediated endocytosis, and peptides which can act as an universal coupling agent, for example, biotin or strepavidin. The linker is designed to not interfere with normal trimerization of fiber protein, to avoid steric hindrance of binding of the fiber protein to a targeted cell, and to serve as a site to introduce new peptide sequence.

The present invention relates to new synthetic receptors. More particularly, the present invention relates to the use of the synthetic receptors for delivering a protein, peptide, drug, prodrug, lipid, nucleic acid, carbohydrate or small molecule into a target cell via receptor-mediated endocytosis. According to the invention, novel synthetic mimics of cell surface receptors have been designed and methods for use of the same are disclosed.

Methods and compositions are provided for delivery of therapeutic nucleic acids to a target cell. A chimeric antigen is provided to encapsulate, bind, or otherwise carry a nucleic acid molecule to a target cell where the chimeric antigen and nucleic acid are internalized by receptor-mediated endocytosis. The chimeric antigen has a nucleic acid interaction domain, a target binding domain, and an immune response domain that may include a target antigen. Targeting is generally provided by the specificity of the target binding domain for a particular target cell receptor, but may also be provided by inclusion of a targeting antigen within the immune response domain. The combined delivery of chimeric antigen and nucleic acid, which may be a siRNA, may be synergistic in certain applications, for example in breaking host tolerance to a virus or in providing immunostimulation.

The present invention describes a system of gene carrier nanoparticles capable of specifically internalize into cancer cells, eg, cancer cells involved in breast cancer, in vitro and in vivo. The system described allows the introduction of therapeutic genes specifically into target cells through NSTR1 receptor-mediated endocytosis of said system, making it possible to provide treatment for this type of conditions, for example by systemic, intravenous, or in situ administration.

The present invention discloses hyaluronic acid- g ‑Folic acid amphiphilic polymer and its application, the main chain is hydrophilic hyaluronic acid, and the side chain is hydrophobic folic acid, which can efficiently and stably load small molecule anticancer drugs and prolong the blood circulation time of drugs; The enrichment amount is high, reaching 12.0%ID / g. After reaching the tumor tissue, the dual-targeted nanomedicine tightly binds to the surface of tumor cells and effectively enters the tumor cells through receptor-mediated endocytosis, and then realizes The drug is released quickly, resulting in a highly effective therapeutic effect. The polymer of the present invention has good biocompatibility and degradability, and is convenient to be excreted from the body; it overcomes the shortcomings of low drug delivery efficiency, less accumulation in tumor sites, low cell endocytosis efficiency, and slow intracellular release; and the method is simple to prepare , the source of raw materials is abundant, and the obtained nanomedicine has excellent freeze-drying redispersibility, which is conducive to large-scale production and application.

The invention discloses a metal-organic matter complex nanometer material as well as a preparation method and applications of the metal-organic matter complex nanometer material, and belongs to the technical field of preparation of antitumor medicines. The preparation method comprises the following steps: adding bovine serum albumin into an alkaline solution, simultaneously dropwise adding coppernitrate solution and 5- nitro-8-hydroxyquinoline solution, and carrying out reaction under the room temperature, so that the metal-organic matter complex nanometer material is obtained through productself-assembly. Through the simple and pollution-free preparation route, the prepared nanometer material has the advantages of good stability, long in-vivo circulation time, good targeting property and biological compatibility, small toxic and side effects, and the like. The provided nanometer material can be applied to tumor treatment as a nanometer medicine, and gathers in the tumor tissue through the EPR effect and the receptor-mediated endocytosis, so that the treatment effect of the metal-organic matter medicine for tumors is improved, and the systemic administration of the metal-organicmatter medicine can be realized.

The invention relates to a phosphorescent iridium complex capable of targeting a tumor cell expressed by integrin alphavbeta3. The phosphorescent iridium complex can be used as a phosphorescent developer to perform targeting recognition and imaging on the tumor cell expressed by integrin alphavbeta3. The invention is characterized in that the phosphorescent iridium complex is a phosphorescent iridium complex of an arginine-glycine-aspartate (RGD peptide) group, an RGD peptide ligand of the iridium complex can be specifically bonded to integrin alphavbeta3 receptors expressed by the surface ofthe tumor cell, the targeting of the iridium complex is transported into the tumor cell by means of the receptor mediated endocytosis, and the intense red phosphorescence of the iridium complex can be observed. The connection mode of the iridium complex and the targeting group is simple, and the iridium complex can be excited by 515 nm visible light, has specificity to the tumor cell expressed byintegrin alphavbeta3 and has high light stability.